Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase i study

Kristin A. Bradley, Ian F. Pollack, Joel M Reid, Peter C. Adamson, Matthew M. Ames, Gilbert Vezina, Susan Blaney, Percy Ivy, Tianni Zhou, Mark Krailo, Gregory Reaman, Minesh P. Mehta

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intravenous bolus 2-5 h prior to standard radiation. The starting dose was 1.7 mg/kg. After first establishing that 5 doses/week for 6 weeks was tolerable, the dose of MGd was escalated until dose-limiting toxicity was reached. Radiation therapy was administered to 54 Gy in 30 once-daily fractions. Forty-four children received MGd at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks. The maximum tolerated dose was 4.4 mg/kg. The primary dose-limiting toxicities were grade 3 and 4 hypertension and elevations in serum transaminases. Median elimination half-life and clearance values were 6.6 h and 25.4 ml/kg/h, respectively. The estimated median survival was 313 days (95% confidence interval, 248-389 days). The maximum tolerated dose of MGd and the recommended phase II dose was 4.4 mg/kg when administered as a daily intravenous bolus in conjunction with 6 weeks of involved field radiation therapy for pediatric intrinsic pontine gliomas.

Original languageEnglish (US)
Pages (from-to)752-758
Number of pages7
JournalNeuro-Oncology
Volume10
Issue number5
DOIs
StatePublished - Oct 2008

Fingerprint

Glioma
Radiotherapy
Maximum Tolerated Dose
Transaminases
Half-Life
Pharmacokinetics
motexafin gadolinium
Confidence Intervals
Radiation
Pediatrics
Hypertension
Brain
Serum

Keywords

  • Motexafin gadolinium
  • Pontine glioma
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood : A Children's Oncology Group phase i study. / Bradley, Kristin A.; Pollack, Ian F.; Reid, Joel M; Adamson, Peter C.; Ames, Matthew M.; Vezina, Gilbert; Blaney, Susan; Ivy, Percy; Zhou, Tianni; Krailo, Mark; Reaman, Gregory; Mehta, Minesh P.

In: Neuro-Oncology, Vol. 10, No. 5, 10.2008, p. 752-758.

Research output: Contribution to journalArticle

Bradley, KA, Pollack, IF, Reid, JM, Adamson, PC, Ames, MM, Vezina, G, Blaney, S, Ivy, P, Zhou, T, Krailo, M, Reaman, G & Mehta, MP 2008, 'Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase i study', Neuro-Oncology, vol. 10, no. 5, pp. 752-758. https://doi.org/10.1215/15228517-2008-043
Bradley, Kristin A. ; Pollack, Ian F. ; Reid, Joel M ; Adamson, Peter C. ; Ames, Matthew M. ; Vezina, Gilbert ; Blaney, Susan ; Ivy, Percy ; Zhou, Tianni ; Krailo, Mark ; Reaman, Gregory ; Mehta, Minesh P. / Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood : A Children's Oncology Group phase i study. In: Neuro-Oncology. 2008 ; Vol. 10, No. 5. pp. 752-758.
@article{771a905037144a129796b964f58c781c,
title = "Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase i study",
abstract = "The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intravenous bolus 2-5 h prior to standard radiation. The starting dose was 1.7 mg/kg. After first establishing that 5 doses/week for 6 weeks was tolerable, the dose of MGd was escalated until dose-limiting toxicity was reached. Radiation therapy was administered to 54 Gy in 30 once-daily fractions. Forty-four children received MGd at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks. The maximum tolerated dose was 4.4 mg/kg. The primary dose-limiting toxicities were grade 3 and 4 hypertension and elevations in serum transaminases. Median elimination half-life and clearance values were 6.6 h and 25.4 ml/kg/h, respectively. The estimated median survival was 313 days (95{\%} confidence interval, 248-389 days). The maximum tolerated dose of MGd and the recommended phase II dose was 4.4 mg/kg when administered as a daily intravenous bolus in conjunction with 6 weeks of involved field radiation therapy for pediatric intrinsic pontine gliomas.",
keywords = "Motexafin gadolinium, Pontine glioma, Radiation therapy",
author = "Bradley, {Kristin A.} and Pollack, {Ian F.} and Reid, {Joel M} and Adamson, {Peter C.} and Ames, {Matthew M.} and Gilbert Vezina and Susan Blaney and Percy Ivy and Tianni Zhou and Mark Krailo and Gregory Reaman and Mehta, {Minesh P.}",
year = "2008",
month = "10",
doi = "10.1215/15228517-2008-043",
language = "English (US)",
volume = "10",
pages = "752--758",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood

T2 - A Children's Oncology Group phase i study

AU - Bradley, Kristin A.

AU - Pollack, Ian F.

AU - Reid, Joel M

AU - Adamson, Peter C.

AU - Ames, Matthew M.

AU - Vezina, Gilbert

AU - Blaney, Susan

AU - Ivy, Percy

AU - Zhou, Tianni

AU - Krailo, Mark

AU - Reaman, Gregory

AU - Mehta, Minesh P.

PY - 2008/10

Y1 - 2008/10

N2 - The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intravenous bolus 2-5 h prior to standard radiation. The starting dose was 1.7 mg/kg. After first establishing that 5 doses/week for 6 weeks was tolerable, the dose of MGd was escalated until dose-limiting toxicity was reached. Radiation therapy was administered to 54 Gy in 30 once-daily fractions. Forty-four children received MGd at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks. The maximum tolerated dose was 4.4 mg/kg. The primary dose-limiting toxicities were grade 3 and 4 hypertension and elevations in serum transaminases. Median elimination half-life and clearance values were 6.6 h and 25.4 ml/kg/h, respectively. The estimated median survival was 313 days (95% confidence interval, 248-389 days). The maximum tolerated dose of MGd and the recommended phase II dose was 4.4 mg/kg when administered as a daily intravenous bolus in conjunction with 6 weeks of involved field radiation therapy for pediatric intrinsic pontine gliomas.

AB - The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intravenous bolus 2-5 h prior to standard radiation. The starting dose was 1.7 mg/kg. After first establishing that 5 doses/week for 6 weeks was tolerable, the dose of MGd was escalated until dose-limiting toxicity was reached. Radiation therapy was administered to 54 Gy in 30 once-daily fractions. Forty-four children received MGd at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks. The maximum tolerated dose was 4.4 mg/kg. The primary dose-limiting toxicities were grade 3 and 4 hypertension and elevations in serum transaminases. Median elimination half-life and clearance values were 6.6 h and 25.4 ml/kg/h, respectively. The estimated median survival was 313 days (95% confidence interval, 248-389 days). The maximum tolerated dose of MGd and the recommended phase II dose was 4.4 mg/kg when administered as a daily intravenous bolus in conjunction with 6 weeks of involved field radiation therapy for pediatric intrinsic pontine gliomas.

KW - Motexafin gadolinium

KW - Pontine glioma

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=56149091530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149091530&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-043

DO - 10.1215/15228517-2008-043

M3 - Article

C2 - 18715950

AN - SCOPUS:56149091530

VL - 10

SP - 752

EP - 758

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 5

ER -